Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Aurinia Pharmaceuticals Inc.

< Previous 1 2 3 4 Next >
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Reports First Quarter 2022 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.